Business Context and Reporting Period
Company: Nephros, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 17, 2017 (Event Date)
Reporting Period: Specific event reporting for a securities transaction closed on March 22, 2017.
Key Financial Metrics
This filing reports a capital raise transaction rather than periodic operating results. Key financial figures include:
- Gross Proceeds: $1,218,000 from the sale of 4,059,994 units.
- Unit Price: $0.30 per unit (consisting of one share of Common Stock and one Warrant).
- Transaction Expenses: Approximately $116,350 in placement agent fees and other expenses.
- Placement Agent Fee: 7.5% of gross proceeds paid to Maxim Group LLC.
- Placement Agent Warrant: Issuance of a warrant to purchase 81,199 shares at an exercise price of $0.33 per share.
Note: The filing does not provide data on revenue, profit, cash flow, margins, or existing debt levels.
Material Changes
The primary material change is the entry into a Securities Purchase Agreement and the subsequent closing of a private placement:
- Capital Structure: Issuance of 4,059,994 shares of Common Stock and warrants to purchase an equal number of shares.
- Liquidity: Influx of gross cash proceeds of $1,218,000.
- Related Party Transactions: Purchases included 83,332 units by two minor children of the CEO (Daron Evans) and 166,666 units by the CFO (Andy Astor), executed on the same terms as other purchasers.
Guidance, Outlook, and Risks
Warrant Terms: Warrants are exercisable for 5 years at $0.30 per share. They must be exercised for cash unless a registration statement is not effective after six months, in which case a cashless exercise option applies.
Registration Rights: The Company agreed to file a registration statement by April 16, 2017, and have it declared effective within 60 to 120 days. Failure to meet these deadlines triggers liquidated damages of 1.0% of the purchase price per month.
Risks: The securities were sold under Section 4(a)(2) of the Securities Act and Regulation D. They are unregistered and cannot be resold in the U.S. absent registration or an applicable exemption.
Investor Verification Checklist
- Verify the closing date of March 22, 2017, and confirmation of fund receipt.
- Confirm the dilution impact of 4,059,994 new shares plus potential warrant exercises.
- Monitor the filing of the Registration Statement by the April 16, 2017 deadline to avoid liquidated damages.
- Review the related party disclosures regarding purchases by the CEO's children and the CFO.
- Check subsequent filings for the net proceeds after deducting the $116,350 in transaction expenses.